What is Invitro International?
develops test kits for non-animal testing applications in the United States and internationally.
IVRO · Verdict
Limited reward · moderate risk
IVRO stands out on balance sheet and volatility, but watch the growth signal.
Based on 88% data coverage
IVRO · Verdict
Current ratio 18.57
Above average
Rev -10.5% CAGR · earnings -68.5%
-8% free-cash-flow margin
0% net margin · 7% ROE
Model-based scoring. For information only — not financial advice.
develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 1.82M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.